Australia’s supermarket giants and fast-food chains may need to brace for a hit to customer demand as the adoption of diabetes and weight-loss drugs like Ozempic accelerates.

That’s according to a new report from Morgan Stanley, which significantly upgraded its outlook for the fast-growing weight-loss drug market – highlighting the stocks and sectors most at risk in the process.